SGLT2 inhibitors prescription for heart failure with LVEF >40% increased from 4.2% to 23.5% from 2021 to 2023, with significant hospital-level variation in adoption.
What are the trends and hospital-level variation in SGLT2 inhibitor adoption at discharge for patients hospitalized with heart failure and LVEF >40%?
SGLT2 inhibitor prescription at discharge for patients with HF and LVEF >40% increased significantly over 2 years following the EMPEROR-Preserved trial, but substantial hospital-level variation remains.
Absolute Event Rate: 0% vs 0%
Importance Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are the first therapy shown to improve clinical outcomes for patients with heart failure (HF) and a left ventricular ejection fraction (LVEF) greater than 40%. Nationwide adoption of SGLT2is in the US since publication of the Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction (EMPEROR-Preserved) in August 2021 is unknown. Objective To examine trends and hospital-level variation in SGLT2i adoption. Design, Setting, and Participants This cohort study included patients with LVEF greater than 40% who were hospitalized for decompensated HF at 1 of 557 sites in the US between July 1, 2021, and September 30, 2023, from the Get With The Guidelines–Heart Failure registry. Main Outcomes and Measures Patient-level trends and site-level variation in prescription rates of SGLT2i at hospital discharge. Site-level variation was quantified using the median odds ratio, which describes the average odds that a patient being treated at one vs another randomly selected hospital would receive SGLT2i therapy at discharge. Results Of 158 849 patients (median IQR age, 76 66-85 years; 89 816 females 56.5%), 22 126 eligible patients (13.9%) with HF and an LVEF greater than 40% were prescribed an SGLT2i at hospital discharge. Quarterly prescription rates increased from 4.2% in July to September 2021 to 23.5% in July to September 2023 ( P for trend lt; .001). SGLT2i prescription was more likely among patients with HF with mildly reduced LVEF (41%-49%) than in those with preserved LVEF (≥50%; 5127 of 27 712 patients 18.5% vs 16 999 of 131 137 patients 13.0%; absolute standardized difference, 16.7%). After adjustment for patient characteristics, there was a high variance between hospitals in the rate of SGLT2i prescription (median odds ratio, 2.12; 95% CI, 2.02-2.25). Among 518 hospitals with 10 or more eligible discharges, 11 hospitals (2.1%) discharged 50% or more of their patients with an SGLT2i prescription, while 232 (44.8%) discharged fewer than 10% of eligible patients with an SGLT2i prescription. Conclusion and Relevance For patients with HF and an LVEF greater than 40%, discharge prescription of SGLT2is increased from 4.2% to 23.5% during the first 2 years after the EMPEROR-Preserved trial demonstrating treatment benefits; however, these rates varied across US hospitals.
Jawad et al. (Mon,) reported a other. SGLT2 inhibitors prescription for heart failure with LVEF >40% increased from 4.2% to 23.5% from 2021 to 2023, with significant hospital-level variation in adoption.